Korro Bio (NASDAQ:KRRO – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
13.2% of Korro Bio shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Comparatively, 6.2% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Korro Bio and TScan Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Korro Bio | $2.38 million | 59.16 | -$117.26 million | ($10.00) | -0.96 |
| TScan Therapeutics | $10.32 million | 2.23 | -$129.77 million | ($0.91) | -0.37 |
Korro Bio has higher earnings, but lower revenue than TScan Therapeutics. Korro Bio is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Korro Bio and TScan Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
| TScan Therapeutics | 1 | 5 | 2 | 0 | 2.12 |
Korro Bio presently has a consensus price target of $16.71, indicating a potential upside of 74.65%. TScan Therapeutics has a consensus price target of $2.67, indicating a potential upside of 684.31%. Given TScan Therapeutics’ higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Korro Bio.
Risk & Volatility
Korro Bio has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
Profitability
This table compares Korro Bio and TScan Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Korro Bio | -1,834.48% | -114.26% | -68.57% |
| TScan Therapeutics | -1,655.35% | -108.72% | -54.47% |
Summary
TScan Therapeutics beats Korro Bio on 9 of the 15 factors compared between the two stocks.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
